Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Downregulation of the large tumor suppressor 2 (LATS2/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia

Leukemia volume 19, pages 2347–2350 (2005)Cite this article

TO THE EDITOR

The human large tumor suppressor 2 (LATS2/KPM) gene, which encodes a novel serine/threonine kinase, has been mapped onto chromosome 13q11–12, a hot spot region for loss of heterozygosity in primary cancers, suggesting that LATS2 might function as a tumor suppressor gene.1 Although chromosome aberrations involving 13q12 have been described in a minority (3–6%) of acute lymphoblastic leukemia (ALL) patients and frequently occur as secondary events after relapse, these patients show an extremely poor outcome.2 DNA methylation is an essential mechanism for the regulation of gene expression in mammalian cells. The promoter of the LATS2 gene contains a defined CpG island and its hypermethylation has been recently associated to an aggressive phenotype in breast cancers.3 All these facts led us to analyze the potential role of the inappropriate expression/promoter hypermethylation of the LATS2 gene in a number of cell lines and primary cells from ALL patients.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  1. Yabuta N, Fujii T, Copeland NG, Gilbert DJ, Jenkins NA, Nishiguchi H et al. Structure, expression, and chromosome mapping of LATS2, a mammalian homologue of the Drosophila tumor suppressor gene lats/warts. Genomics 2000; 63: 263–270.

    Article  CAS  Google Scholar 

  2. Heerema NA, Sather HN, Sensel MG, Lee MK, Hutchinson RJ, Nachman JB et al. Abnormalities of chromosome bands 13q12 to 13q14 in childhood acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 3837–3844.

    Article  CAS  Google Scholar 

  3. Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y et al. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 2005; 11: 1380–1385.

    Article  CAS  Google Scholar 

  4. Kamikubo Y, Takaori-Kondo A, Uchiyama T, Hori T . Inhibition of cell growth by conditional expression of kpm, a human homologue of Drosophila warts/lats tumor suppressor. J Biol Chem 2003; 278: 17609–17614.

    Article  CAS  Google Scholar 

  5. Li Y, Pei J, Xia H, Ke H, Wang H, Tao W . Lats2, a putative tumor suppressor, inhibits G1/S transition. Oncogene 2003; 22: 4398–4405.

    Article  CAS  Google Scholar 

  6. Ke H, Pei J, Ni Z, Xia H, Qi H, Woods T et al. Putative tumor suppressor Lats2 induces apoptosis through downregulation of Bcl-2 and Bcl-x(L). Exp Cell Res 2004; 298: 329–338.

    Article  CAS  Google Scholar 

  7. McPherson JP, Tamblyn L, Elia A, Migon E, Shehabeldin A, Matysiak-Zablocki E et al. Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity. EMBO J 2004; 23: 3677–3688.

    Article  CAS  Google Scholar 

  8. Powzaniuk M, McElwee-Witmer S, Vogel RL, Hayami T, Rutledge SJ, Chen F et al. The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor. Mol Endocrinol 2004; 18: 2011–2023.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by Grants from Fondo de Investigacion Sanitaria (FIS, Spain) 02/1299, 03/0141, 01/0013-01, 01/F018; Junta de Andalucia 03/143; 03/144 and funds from Fundacion IMABIS (Malaga, Spain), Navarra Government (31/2002); RETIC C03/10, Fundación de Investigación Médica Mutua Madrileña Automovilista. ‘UTE project CIMA’ and Asociacion Medicina e Investigacion (AMI)

Author information

Authors and Affiliations

  1. Department of Hematology, Hospital Carlos Haya, Malaga, Spain

    A Jiménez-Velasco, M Barrios, G Navarro & A Heiniger

  2. Department of Hematology, Hospital Reina Sofia, Cordoba, Spain

    J Román-Gómez & A Torres

  3. Division of Cancer, Foundation for Applied Medical Research, Area of Cell Therapy and Hematology Service, Clínica Universitaria, Universidad de Navarra, Navarra, Spain

    X Agirre, I Vázquez & F Prósper

Authors
  1. A Jiménez-Velasco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Román-Gómez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. X Agirre
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Barrios
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Navarro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I Vázquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F Prósper
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Torres
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A Heiniger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Jiménez-Velasco.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jiménez-Velasco, A., Román-Gómez, J., Agirre, X. et al. Downregulation of the large tumor suppressor 2 (LATS2/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia. Leukemia 19, 2347–2350 (2005). https://doi.org/10.1038/sj.leu.2403974

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403974

This article is cited by

Search

Advanced search

Quick links